Trials / Completed
CompletedNCT04736602
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptorelin pamoate 15mg | Intramuscular injection (IM) |
Timeline
- Start date
- 2021-03-27
- Primary completion
- 2022-02-09
- Completion
- 2022-09-03
- First posted
- 2021-02-03
- Last updated
- 2024-08-01
- Results posted
- 2024-08-01
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04736602. Inclusion in this directory is not an endorsement.